Short answer
Voyager Therapeutics, Inc. (VYGR) filed an 8-K current report with the SEC on July 13, 2026 reporting Item 8.01 (Other Events). VY1706 GLP toxicology showed favorable tolerability in non-human primates through six months.
Voyager Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 8.01 · Other Events
- VY1706 GLP toxicology showed favorable tolerability in non-human primates through six months
- No adverse CNS, dorsal root ganglia, or peripheral-organ findings at doses up to 5 × 10¹³ vector genomes/kg
- Single intravenous dose achieved up to 75% MAPT mRNA and tau-protein lowering in key Alzheimer’s brain regions
- ALPL-mediated blood-brain-barrier transport supports potential cross-species translation into human development
- FDA-cleared trial expected to begin first-in-human dosing in the second half of 2026, creating a near-term clinical catalyst
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Voyager Therapeutics, Inc. 8-K filings
Get the next VYGR 8-K as it lands
Follow VYGR for push alerts, or ask the research agent what this filing means.